Aldeyra Therapeutics Shareholders Are Encouraged To Reach Out To Johnson Fistel For More Information About Potentially Recovering Their Losses

(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focuses on Aldeyra Therapeutics executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Aldeyra Therapeutics securities?
If you purchased Aldeyra Therapeutics securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.

Or for more information, contact Jim Baker at... or (619) 814-4471.
There is no cost or obligation to you.

Background of the investigation
On March 17, 2026, Aldeyra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) declined to approve its lead investigational drug, reproxalap, for the treatment of dry eye disease. According to the company's disclosure, the FDA cited insufficient evidence of efficacy.

Following the announcement, Aldeyra Therapeutics' stock declined by more than 70% in early morning trading on March 17, 2026.

In light of this disclosure, Johnson Fistel is investigating whether Aldeyra Therapeutics complied with the federal securities laws. If you suffered losses from your investment in Aldeyra Therapeutics stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit .

Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm's effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs' securities law firm in the United States, based on the total dollar value of final recoveries.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 |... |...

MENAFN17032026004107003653ID1110873165